Aroa Biosurgery (ASX:ARX) Long-Term Capital Lease Obligation : A$5.90 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Long-Term Capital Lease Obligation?

Aroa Biosurgery's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was A$5.90 Mil.

Aroa Biosurgery's quarterly Long-Term Capital Lease Obligation declined from Mar. 2023 (A$6.13 Mil) to Sep. 2023 (A$0.00 Mil) but then increased from Sep. 2023 (A$0.00 Mil) to Mar. 2024 (A$5.90 Mil).

Aroa Biosurgery's annual Long-Term Capital Lease Obligation increased from Mar. 2022 (A$4.91 Mil) to Mar. 2023 (A$6.13 Mil) but then declined from Mar. 2023 (A$6.13 Mil) to Mar. 2024 (A$5.90 Mil).

Aroa Biosurgery Long-Term Capital Lease Obligation Historical Data

The historical data trend for Aroa Biosurgery's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Long-Term Capital Lease Obligation Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Capital Lease Obligation

1.82

5.25

4.91

6.13

5.90

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial			4.91	-	6.13	-	5.90

Aroa Biosurgery (ASX:ARX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Aroa Biosurgery Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines